Purpose

To investigate the safety of Nivolumab in combination with Ipilimumab in subjects with previously untreated advanced or metastatic Renal Cell Cancer.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Type of Participant and Target Disease Characteristics 1. Advanced or metastatic RCC 2. Histologically confirmed, previously untreated (treatment-naive) RCC 3. No prior systemic therapy for RCC except for one prior adjuvant or neoadjuvant therapy for completely resectable RCC 4. Measurable disease as per RECIST 1.1. Subject must have extracranial metastasis as measurable disease 5. Karnofsky Performance Status (KPS) of at least 70% for Cohort 1, 2, and 3; KPS of 50-60% for Cohort 4 6. Tumor tissue need be received by the central vendor (block or unstained slides). Note: Fine Needle Aspiration (FNA)and bone metastases samples are not acceptable for submission.

Exclusion Criteria

  1. Medical Conditions 1. Subjects with any active autoimmune disease or a history of known autoimmune disease 2. Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured 3. Known HIV or AIDS-related illness 4. Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection. 2. Prior/Concomitant Therapy 1. Prior systemic treatment in the metastatic setting with Vascular epithelial growth factor(VEGF) or VEGF receptor targeted therapy 2. Prior treatment with an anti-Programmed Death (PD) -1, anti-PD-L1, anti-PD-L2, anti-cluster of differentiation 137 (CD137), or anti-cytotoxic T-lymphocyte-associated antigen 4(CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. This includes the utilization of these agents in the neo-adjuvant or adjuvant setting. 3. Anti-cancer therapy less than 28 days prior to the first dose of study drug or palliative, focal radiation therapy less than 14 days prior to the first dose of study drug. Other protocol defined inclusion/exclusion criteria apply

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
ccRCC KPS ≥ 70%
Clear-Cell Renal Cell Carcinoma (ccRCC) with Karnofsky Performance Status (KPS) ≥ 70%
  • Drug: Nivolumab
    Specified dose on specified day
    Other names:
    • BMS-936558
    • Opdivo
  • Drug: Ipilimumab
    Specified Dose on Specified Day
    Other names:
    • Yervoy
    • BMS-734016
Experimental
Non-ccRCC, KPS ≥ 70%
Non Clear-Cell Renal Cell Carcinoma (nccRCC) with KPS ≥ 70%
  • Drug: Nivolumab
    Specified dose on specified day
    Other names:
    • BMS-936558
    • Opdivo
  • Drug: Ipilimumab
    Specified Dose on Specified Day
    Other names:
    • Yervoy
    • BMS-734016
Experimental
RCC with non-active Brain Mets, KPS ≥70%
Renal Cell Carcinoma (RCC) with non-active Brain Metastases, with KPS ≥70%
  • Drug: Nivolumab
    Specified dose on specified day
    Other names:
    • BMS-936558
    • Opdivo
  • Drug: Ipilimumab
    Specified Dose on Specified Day
    Other names:
    • Yervoy
    • BMS-734016
Experimental
any RCC with KPS 50%-60%
Renal Cell Carcinoma (RCC), regardless of any histology or existing non-active brain metastasis, with KPS 50%-60%
  • Drug: Nivolumab
    Specified dose on specified day
    Other names:
    • BMS-936558
    • Opdivo
  • Drug: Ipilimumab
    Specified Dose on Specified Day
    Other names:
    • Yervoy
    • BMS-734016

More Details

Status
Completed
Sponsor
Bristol-Myers Squibb

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.